IGBA, the International Generic and Biosimilar Medicines Association (IGBA), representing global manufacturers of generic and biosimilar medicines, announced today that Shinichiro Hirose, Director of International Affairs at the Japanese Generic Medicines Association (JGA) is taking over the position of IGBA Chair for 2025 from Adrian van den Hoven, Director of Medicines for Europe. Jim Keon, President of the Canadian Generic Pharmaceutical Association, will take over the position of IGBA Vice-Chair for 2025.
The International Generic and Biosimilar medicines Association (IGBA) announced today the annual leadership change of its CEO Advisory Committee (AC). Lucas Sigman, CEO of Insud Pharma, has been appointed Chair and Allan Oberman, President and CEO of Apotex, Vice-Chair.
25 NOVEMBER 2024, BUSAN, SOUTH KOREA – This statement is delivered on behalf of IFPMA, GSCF, and IGBA, who collectively represent innovative, generic, and biosimilars pharmaceutical companies, as well as consumer healthcare manufacturers.
- High-Level Statement: Comprehensive approach for a treaty to end plastics pollution: Perspectives from the biopharmaceutical and consumer health industries (November 2024)
- Global Biosimilars Week 2024 to Focus on Advancing Access to Biosimilars (November 2024)
- AMIP, the Moroccan Pharmaceutical Industry Association, joins IGBA (September 2024)
- IGBA identifies streamlined development through reduced comparative clinical studies and appropriate use of global comparator product as key to greater biosimilar access (July 2024)
